Business
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease modelsSafety data from Phase 1 on healthy volunteers and initial efficacy signals from ex-vivo functional assays expected by year-end 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver d
About this update from Genfit Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease models","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Safety data from Phase 1 on healthy volunteers and initial efficacy signals from ex-vivo functional assays expected by year-end 2025","length":132,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":252,"olType":false},{"type":"text","content":"Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today presents promising new preclinical data in ACLF at The Liver Meeting® 2025 with nitazoxanide (NTZ). GENFIT is advancing NTZ through a novel formulation, investigational drug G1090N, which serves as the cornerstone of our ACLF pipeline and reflects our commitment to addressing critical unmet needs in liver disease. G1090N was designed to optimize dose-response and permit sufficient dosing flexibility in patients with ACLF, who are known to have varying degrees of renal or hepatic impairment or failure.","length":768,"tagName":"p"},{"type":"text","content":"Dr. Jonel Trebicka, MD, PHD, Head of Department and Professor of Medicine, University of Münster, Germany, commented: “These preclinical findings demonstrate beneficial effects on systemic inflammation and organ failure in ACLF disease models and add to a growing body of evidence for this therapy. We eagerly await the upcoming safety data from G1090N in healthy volunteers, along with potential efficacy signals on key biomarkers from ex-vivo approaches. Positive results at the end of this year could pave the way to further clinical development.”","length":550,"tagName":"p"},{"type":"text","content":"ACLF presents as a syndrome defined by a combination of hepatic and extrahepatic organ dysfunctions and failures and a uniformly poor prognosis. In patients with liver cirrhosis and acute hepatic decompensation, ACLF can be triggered by a precipitating event (e.g. an infection) that leads to a progressive functional deterioration of multiple organs with high short-term mortality (23% to 74% mortality at 28 days1).","length":417,"tagName":"p"},{"type":"text","cont...